4. Large, Automated Administrative and Clinical Databases Available for Pharmacoepidemiology Studies in Japan

[1]  A. Koizumi,et al.  Usefulness of a large automated health records database in pharmacoepidemiology , 2011, Environmental health and preventive medicine.

[2]  Kazuhito Shiosakai,et al.  Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan , 2012, Pharmaceutics.

[3]  T. Nakahata,et al.  Prescription trends for treatment of paediatric gastroenteritis at a Japanese hospital between 1997 and 2007 , 2010, Journal of clinical pharmacy and therapeutics.

[4]  H. Une,et al.  A comparison of disease-specific medical expenditures in Japan using the principal diagnosis method and the proportional distribution method. , 2012, Journal of evaluation in clinical practice.

[5]  S. Ikeda,et al.  Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. , 2011, Internal medicine.

[6]  J. Hallas.  Drug utilization statistics for individual‐level pharmacy dispensing data , 2005, Pharmacoepidemiology and drug safety.

[7]  H Watanabe,et al.  SS-MIX: A Ministry Project to Promote Standardized Healthcare Information Exchange , 2011, Methods of Information in Medicine.

[8]  S. Kosugi,et al.  Effect of HMG-CoA reductase inhibitors on blood pressure in hypertensive patients treated with blood pressure-lowering agents: retrospective study using an anti-hypertensive drug database. , 2012, European review for medical and pharmacological sciences.

[9]  Toshiharu Fujita,et al.  Assessing the Effects of Non-steroidal Anti-inflammatory Drugs on Antihypertensive Drug Therapy Using Post-Marketing Surveillance Database , 2008, Journal of epidemiology.

[10]  S. Ikeda,et al.  Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. , 2011, Internal medicine.

[11]  Takuhiro Yamaguchi,et al.  The Impact in Japan of Regulatory Action on Prescribing of Dopamine Receptor Agonists , 2011, Drug safety.